Orgenesis Inc

Company Profile

Orgenesis Inc had its IPO on 2012-03-12 under the ticker symbol ORGS.

The company operates in the Healthcare sector and Biotechnology industry. Orgenesis Inc has a staff strength of 167 employees.

Stock update

Shares of Orgenesis Inc opened at $0.7 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.68 - $0.73, and closed at $0.69.

This is a -2.13% slip from the previous day's closing price.

A total volume of 26,430 shares were traded at the close of the day’s session.

In the last one week, shares of Orgenesis Inc have increased by +18.12%.

Orgenesis Inc's Key Ratios

Orgenesis Inc has a market cap of $21.42 million, indicating a price to book ratio of 1.6996 and a price to sales ratio of 1.779.

In the last 12-months Orgenesis Inc’s revenue was $35.63 million with a gross profit of $36.03 million and an EBITDA of $-3929000. The EBITDA ratio measures Orgenesis Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Orgenesis Inc’s operating margin was -17.14% while its return on assets stood at -6.49% with a return of equity of -38%.

In Q1.6666666666667, Orgenesis Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 3.1%.

Orgenesis Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.54 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Orgenesis Inc’s profitability.

Orgenesis Inc stock is trading at a EV to sales ratio of 2.6297 and a EV to EBITDA ratio of -6.0303. Its price to sales ratio in the trailing 12-months stood at 1.779.

Orgenesis Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$54.77 million

Total Liabilities

$12.71 million

Operating Cash Flow

$0

Capital Expenditure

$511000

Dividend Payout Ratio

0%

Orgenesis Inc ended 2024 with $54.77 million in total assets and $0 in total liabilities. Its intangible assets were valued at $54.77 million while shareholder equity stood at $23.97 million.

Orgenesis Inc ended 2024 with $0 in deferred long-term liabilities, $12.71 million in other current liabilities, 3000.00 in common stock, $-129577000.00 in retained earnings and $3.70 million in goodwill. Its cash balance stood at $180000.00 and cash and short-term investments were $180000.00. The company’s total short-term debt was $2,616,000 while long-term debt stood at $17.83 million.

Orgenesis Inc’s total current assets stands at $9.30 million while long-term investments were $31.48 million and short-term investments were $0. Its net receivables were $8.03 million compared to accounts payable of $3.83 million and inventory worth $34000.00.

In 2024, Orgenesis Inc's operating cash flow was $0 while its capital expenditure stood at $511000.

Comparatively, Orgenesis Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.69

52-Week High

$2.64

52-Week Low

$0.38

Analyst Target Price

$6

Orgenesis Inc stock is currently trading at $0.69 per share. It touched a 52-week high of $2.64 and a 52-week low of $2.64. Analysts tracking the stock have a 12-month average target price of $6.

Its 50-day moving average was $0.96 and 200-day moving average was $1.45 The short ratio stood at 3.85 indicating a short percent outstanding of 0%.

Around 1180.3% of the company’s stock are held by insiders while 1256.9% are held by institutions.